Edward J Unsworth

US Patent:

6653284, Nov 25, 2003

Filed:

May 14, 2001

Appl. No.:

09/853666

Inventors:

Reiner L. Gentz - Rockville MD
Arvind Chopra - Gaithersburg MD
Parveen Kaushal - Silver Springs MD
Thomas Spitznagel - Vienna VA
Edward Unsworth - Kensington MD
Fazal Khan - Gaithersburg MD

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

A61K 3818

US Classification:

514 12, 514 2, 424 851

Abstract:

The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.

US Patent:

6802967, Oct 12, 2004

Filed:

Mar 6, 2002

Appl. No.:

10/091029

Inventors:

Junichi Masuda - North Bethesda MD
Edward J. Unsworth - Kensington MD
Jeffrey A. Kowalak - Alexandria VA
Sanford P. Markey - Bethesda MD

Assignee:

Shimadzu Corporation - Kyoto
The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

B01D 1508

US Classification:

2101982, 210656, 210659, 422 70

Abstract:

Liquid chromatography based on the difference of two or more kinds of separation modes, (e. g. , chemical or physical properties of analytes) may improve separations when samples contain complex mixtures. In this invention, the analytes separated on the 1st analysis system (consisting of the 1st column and the 1st mobile phase) will be trapped onto individual trapping columns. Then the trapped analytes will be loaded onto the 2nd analysis system consisting of the 2nd column and the 2nd mobile phase. This invention has the trapping and loading mechanism consisting of a combination of switching valves necessary to produce the serial separations. Also this invention has the capability to affect online desalting when it is needed depending on a detector or the nature of the analyte mixture.

US Patent:

6869927, Mar 22, 2005

Filed:

Jun 2, 2000

Appl. No.:

09/585541

Inventors:

Reiner L. Gentz - Rockville MD, US
Arvind Chopra - Gaithersburg MD, US
Parveen Kaushal - Silver Spring MD, US
Thomas Spitznagel - Vienna VA, US
Edward Unsworth - Kensington MD, US
Fazal Khan - Gaithersburg MD, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

A01N037/18
C12P021/06
A61K038/00
C12N015/00
C07H021/04

US Classification:

514 2, 514 12, 514925, 435 691, 435 694, 435243, 4353201, 435325, 530300, 530324, 530328, 530399, 530402, 536 2351

Abstract:

The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.

US Patent:

7101548, Sep 5, 2006

Filed:

Aug 16, 2001

Appl. No.:

09/931700

Inventors:

Frank Cuttitta - Adamstown MD, US
Alfredo Martinez - McLean VA, US
Mae Jean Miller - Monrovia MD, US
Edward J. Unsworth - Kensington MD, US
William Hook - Wheaton MD, US
Thomas Walsh - Bethesda MD, US
Karen Gray - Gaithersburg MD, US
Charles Macri - Kensington MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/395

US Classification:

4241301, 435 4, 435 71, 4241381, 4241391, 4241521

Abstract:

The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.

US Patent:

7364719, Apr 29, 2008

Filed:

Oct 3, 2003

Appl. No.:

10/529118

Inventors:

Frank Cuttitta - Adamstown MD, US
Alfredo Martinez - Bethesda MD, US
William G. Stetler-Stevenson - Kensington MD, US
Edward J. Unsworth - Kensington MD, US
Juan M. Saavedra - Bethesda MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 49/00

US Classification:

424 91, 424 111, 424 165, 424 169, 424 92

Abstract:

Methods and compounds are described for regulating blood pressure in a subject. Specific embodiments are methods for reversing vasodilation of blood vessels, by administering to a subject a therapeutically effective amount peptide AM(11-22). The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock. Other specific embodiments are methods for reversing vasoconstriction of blood vessels, by administering to a subject a therapeutically effect amount of an inhibitor of AM(11-22), sufficient to reduce hypertension in the subject. Compounds and pharmaceutical compositions are also provided, as are kits.

US Patent:

20040063639, Apr 1, 2004

Filed:

Oct 30, 2003

Appl. No.:

10/695957

Inventors:

Reiner Gentz - Belo Horizonte-Mg, BR
Arvind Chopra - Gaithersburg MD, US
Parveen Kaushal - Silver Spring MD, US
Thomas Spitznagel - Vienna VA, US
Edward Unsworth - Kensington MD, US
Fazal Khan - Gaithersberg MD, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

A61K038/18

US Classification:

514/012000

Abstract:

The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.

US Patent:

20070004630, Jan 4, 2007

Filed:

Sep 5, 2006

Appl. No.:

11/517599

Inventors:

Frank Cuttitta - Adamstown MD, US
Alfredo Martinez - McLean VA, US
Mae Miller - Monrovia MD, US
Edward Unsworth - Kensington MD, US
William Hook - Wheaton MD, US
Thomas Walsh - Bethesda MD, US
Karen Gray - Gaithersburg MD, US
Charles Macri - Kensington MD, US

International Classification:

A61K 39/395
A61K 38/22

US Classification:

514012000, 424145100

Abstract:

The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.

US Patent:

20090136524, May 28, 2009

Filed:

Dec 19, 2008

Appl. No.:

12/340211

Inventors:

Vivian Takafuji - Alexandria VA, US
Xin Wei Wang - Rockville MD, US
Edward J. Unsworth - Westport MA, US
Paul K. Goldsmith - Rockville MD, US

International Classification:

A61K 39/395
G01N 33/68
G01N 33/53
C12Q 1/02
A61K 38/10
C07K 14/435
C07H 21/00
A61P 35/00
C12N 15/63
C07K 16/00
A61K 38/17
A61K 38/08
C12Q 1/68
C12N 5/00

US Classification:

4241741, 436 87, 436501, 435 29, 435 6, 435375, 514 17, 514 16, 514 15, 514 14, 514 13, 514 12, 530395, 435325, 5303882, 5303873, 5303879, 5303911, 536 2353, 4353201

Abstract:

Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.